Shukra Pharmaceuticals Ltd

Shukra Pharmaceuticals Ltd

Shukra Pharmaceuticals Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 22/08/2026 to consider and approve AGM, name change, object clause change, and other matters.

Shukra Pharmaceuticals Ltd

Shukra Pharmaceuticals Ltd has entered into a Term Sheet with Borns Medical Robotics Pte Ltd for a strategic joint venture to design, manufacture, and distribute Al-enabled surgical robotic systems in India and the Asia-Pacific region.

Shukra Pharmaceuticals Ltd

Shukra Pharmaceuticals Ltd has approved a proposal to change its name to 'Shukra Medtech Ltd' and expand its main objects to include medical technology, subject to shareholder and regulatory approvals.

Shukra Pharmaceuticals Ltd

Shukra Pharmaceuticals Ltd has been listed and admitted to dealings on the Main Board of the National Stock Exchange of India Limited (NSE) with effect from August 14, 2026. The company's equity shares will continue to be listed and traded on the BSE Limited (BSE).

Shukra Pharmaceuticals Ltd

Shukra Pharmaceuticals Ltd, a pharmaceutical company, has announced its direct listing on the National Stock Exchange (NSE), with trading to commence on August 14, 2026. The company has marked this milestone with a ceremonial opening bell ringing at the NSE Exchange Plaza, Mumbai. This transition represents a dual-listing strategy aimed at expanding the company's visibility, attracting a broader base of institutional and retail investors, and deepening market liquidity.

Shukra Pharmaceuticals Ltd

Shukra Pharmaceuticals Ltd has published unaudited financial results for the first quarter ended June 30, 2026, which have been posted on the company's website.

Shukra Pharmaceuticals Ltd

Shukra Pharmaceuticals Ltd has announced its unaudited standalone financial results for the quarter ended June 30, 2026, with a net profit of ₹1,502.98 lakhs and earnings per share of ₹0.34.

Shukra Pharmaceuticals Ltd

Shukra Pharmaceuticals Ltd has announced its quarterly results for the period ended June 30, 2026, with a net profit of ₹1,502.98 lakhs. The company's revenue from operations was ₹2,352.23 lakhs, and its total income from operations was ₹2,406.20 lakhs. The results have been reviewed by the Audit Committee and approved by the Board of Directors.

Shukra Pharmaceuticals Ltd

Shukra Pharmaceuticals Ltd has revised the date of its Board Meeting from 11/08/2026 to 12/08/2026 to consider unaudited financial results for the quarter ended 30/06/2026 and other business.

Shukra Pharmaceuticals Ltd

Shukra Pharmaceuticals Ltd has informed BSE that the meeting of the Board of Directors is scheduled on 11/08/2026 to consider and approve unaudited financial results for the quarter ended on 30th June, 2026, along with the Auditor's Limited Review Report.

Shukra Pharmaceuticals Ltd

Shukra Pharmaceuticals Ltd announced the closure of its trading window for designated persons, including promoters, directors, KMPs, and their immediate relatives. This measure, effective July 1, 2026, is in accordance with SEBI (Prohibition of Insider Trading) Regulations, 2015. The trading window will remain closed until 48 hours after the company declares its unaudited financial results for the quarter ended June 30, 2026. This is a standard compliance procedure ahead of quarterly earnings announcements to prevent insider trading.